The Linerixibat Market is gaining traction in the pharmaceutical industry due to its potential to treat cholestatic pruritus in patients with primary biliary cholangitis (PBC). As an investigational IBAT inhibitor, Linerixibat has demonstrated promising results in clinical trials, making it a key player in this therapeutic space. This article provides an in-depth analysis of the Linerixibat...